| ID | 118993 |
| Author |
Yamashita, H
Kanaiso Hospital
Bando, Hiroshi
Kanaiso Hospital|Tokushima University|Medical Research|Japan Low Carbohydrate Diet Promotion Association
KAKEN Search Researchers
Kato, Y
Kanaiso Hospital
Ogura, K
Kanaiso Hospital
Kato, Y
Kanaiso Hospital
Sueki, E
Kanaiso Hospital
|
| Keywords | Semaglutide (Rybelsus)
Gastrointestinal adverse events (GIAEs)
Glucagon-like-peptide 1 receptor agonist (GLP1-RA)
Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC)
Semaglutide Treatment Effect in People with Obesity (STEP)
Peptide InnOvatioN for Early diabEtes tReatment (PIONEER)
|
| Content Type |
Journal Article
|
| Description | Background: As glucagon-like-peptide 1 receptor agonist (GLP1-RA), oral semaglutide (Rybelsus) has been latest topic.
Case presentation: Patient is 72-year-old male with T2D, obesity, fatty liver and hypertension. He showed BMI 32.4 kg/m2 and HbA1c 8.1% in Nov 2021. Results: He started Rybelsus 3-7mg/day, and HbA1c and weight decreased for 8.1% to 7.0% and 92kg to 86.5kg with ALT/GGT improvement without gastrointestinal adverse events (GIAEs). Discussion: This case has arteriosclerotic cardiovascular disease (ASCVD). From cardiovascular outcome trials (CVOTs), semaglutide group revealed lower odd ratio (OR) for less CV death, as 0.47 of exenatide, 0.46 of dulaglutide and 0.43 of lixisenatide. |
| Journal Title |
SunText Review of Medical & Clinical Research
|
| ISSN | 27664813
|
| Publisher | SunText Reviews
|
| Volume | 3
|
| Issue | 3
|
| Start Page | 161
|
| Published Date | 2022-07-31
|
| Rights | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
| DOI (Published Version) | |
| URL ( Publisher's Version ) | |
| FullText File | |
| language |
eng
|
| TextVersion |
Publisher
|
| departments |
Medical Sciences
|
